Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2013 3
2014 20
2015 138
2016 201
2017 190
2018 221
2019 180
2020 14
Text availability
Article attribute
Article type
Publication date

Search Results

822 results
Results by year
Filters applied: . Clear all
Page 1
Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China.
Li J, Wang S, Wang Y, Wang X, Wang H, Feng J, Zhang Q, Sun T, Ouyang Q, Yin Y, Liu Y, Geng C, Yan M, Jiang Z. Li J, et al. Oncologist. 2017 Nov;22(11):1333-1338. doi: 10.1634/theoncologist.2017-0088. Epub 2017 Aug 10. Oncologist. 2017. PMID: 28798274 Free PMC article.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. von Minckwitz G, et al. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. N Engl J Med. 2019. PMID: 30516102 Clinical Trial.
Trastuzumab in the Treatment of Breast Cancer.
Maximiano S, Magalhães P, Guerreiro MP, Morgado M. Maximiano S, et al. BioDrugs. 2016 Apr;30(2):75-86. doi: 10.1007/s40259-016-0162-9. BioDrugs. 2016. PMID: 26892619 Review.
ABP 980: A Trastuzumab Biosimilar.
Dhillon S. Dhillon S. BioDrugs. 2018 Oct;32(5):511-514. doi: 10.1007/s40259-018-0305-2. BioDrugs. 2018. PMID: 30264234 Review.
The use of trastuzumab in New Zealand women with breast cancer.
Lawrenson R, Lao C, Campbell I, Harvey V, Brown C, Seneviratne S, Edwards M, Elwood M, Kuper-Hommel M. Lawrenson R, et al. Asia Pac J Clin Oncol. 2018 Apr;14(2):e152-e160. doi: 10.1111/ajco.12766. Epub 2017 Aug 30. Asia Pac J Clin Oncol. 2018. PMID: 28856817
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. von Minckwitz G, et al. N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. N Engl J Med. 2017. PMID: 28581356 Free PMC article. Clinical Trial.
Efficacy and safety of the trastuzumab biosimilar candidate CT-P6.
Esteva FJ, Saeki T, Kim H, Stebbing J. Esteva FJ, et al. Future Oncol. 2018 Aug;14(19):1909-1919. doi: 10.2217/fon-2017-0679. Epub 2018 Feb 27. Future Oncol. 2018. PMID: 29482364 Review.
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer.
Rinnerthaler G, Gampenrieder SP, Greil R. Rinnerthaler G, et al. Int J Mol Sci. 2019 Mar 5;20(5):1115. doi: 10.3390/ijms20051115. Int J Mol Sci. 2019. PMID: 30841523 Free PMC article. Review.
Trastuzumab cardiotoxicity: from clinical trials to experimental studies.
Nemeth BT, Varga ZV, Wu WJ, Pacher P. Nemeth BT, et al. Br J Pharmacol. 2017 Nov;174(21):3727-3748. doi: 10.1111/bph.13643. Epub 2016 Nov 25. Br J Pharmacol. 2017. PMID: 27714776 Free PMC article. Review.
822 results
Jump to page